Skip to main content
Fig. 1 | BMC Medical Genomics

Fig. 1

From: Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients

Fig. 1

Schematic of secreto-transcriptomic approach for identifying putative liquid biopsy prognostic markers. Label-free quantitative (LFQ) proteomics is used to identify differentially secreted proteins from different BC subtypes. Proteotranscriptomic analysis of TCGA/METABRIC patient data identifies luminal or basal genes showing Secretion-Correlated mRNA Expression Pattern (SeCEP). Kaplan-Meyer (KM) analysis then identifies unique combinations of SeCEP genes showing mRNA co-overexpression patterns of prognostic significance

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us